Navigation Links
Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference (ECCO)
Date:9/26/2007

or is cleaved to release the active drug.

About Pancreatic Cancer

The American Cancer Society estimates that 37,170 patients will be diagnosed with pancreatic cancer in the United States in 2007, and approximately 33,370 patients will die from the disease. Only 15-20% of newly diagnosed patients are eligible for surgery, which is typically followed by radiation and chemotherapy. Patients with inoperable pancreatic cancer are treated with radiation and chemotherapy, or in the case of metastatic disease, chemotherapy alone as the advantages of radiation are reduced.

About Threshold Pharmaceuticals

Threshold is a biotechnology company focused on the discovery and development of small molecule therapeutics for the potential treatment of cancer. By selectively targeting abnormally-proliferating tumor cells, the Company's drug candidates are designed to be potentially more effective and less toxic to healthy tissues than conventional treatments. For additional information, please visit our website (http://www.thresholdpharm.com).

Forward-Looking Statements

Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Threshold's product candidates, clinical trial progress and results, potential therapeutic uses and benefits of our product candidates and financial projections. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Threshold's ability to commence, enroll or complete its anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Th
'/>"/>

SOURCE Threshold Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... May 27, 2015 Mapi Pharma Ltd. ... of $10 million in the company in a Series A ... CEO Mr. Ehud Marom . The funding will be ... is sufficient to advance the company,s lead product, the Glatiramer ... at Phase II, up to the initiation of the single ...
(Date:5/27/2015)... Colo., May 27, 2015 Encision Inc. (OTCQB:ECIA), ... prevents dangerous stray electrosurgical burns in minimally invasive surgery, ... quarter and fiscal year ended March 31, 2015. ... million for a quarterly net loss of $349 thousand, ... revenue of $2.504 million for a net loss of ...
(Date:5/27/2015)... May 27, 2015  The World MS Day campaign ... organizations globally to raise awareness of multiple sclerosis and those ... and support that will move us closer a world ... circling the globe, including the National MS Society, have ... The 2015 World MS Day campaign theme is "access." ...
Breaking Medicine Technology:Mapi Pharma Closes $10 Million Investment Led by Shavit Capital 2Encision Reports Fourth Quarter And Fiscal Year 2015 Results 2Encision Reports Fourth Quarter And Fiscal Year 2015 Results 3Encision Reports Fourth Quarter And Fiscal Year 2015 Results 4Encision Reports Fourth Quarter And Fiscal Year 2015 Results 5Encision Reports Fourth Quarter And Fiscal Year 2015 Results 6People Around The World Are Sharing What Makes Them Stronger Than Multiple Sclerosis 2People Around The World Are Sharing What Makes Them Stronger Than Multiple Sclerosis 3People Around The World Are Sharing What Makes Them Stronger Than Multiple Sclerosis 4People Around The World Are Sharing What Makes Them Stronger Than Multiple Sclerosis 5
... BEIJING, Nov. 9, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ... biopharmaceutical products in China, announced today the positive top-line ... proprietary inactivated vaccine against human enterovirus 71 (EV71), which ... Phase II results for the EV71 vaccine showed a ...
... HARBIN, China, Nov. 9, 2011 /PRNewswire-Asia/ -- China Sky One ... CSKI ), a leading fully integrated pharmaceutical company producing ... announced financial results for the third quarter of 2011. ... Financial Highlights , Total revenues decreased 26.6% year-over-year to ...
Cached Medicine Technology:Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease 2Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease 3Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease 4China Sky One Medical Announces Third Quarter 2011 Results 2China Sky One Medical Announces Third Quarter 2011 Results 3China Sky One Medical Announces Third Quarter 2011 Results 4China Sky One Medical Announces Third Quarter 2011 Results 5China Sky One Medical Announces Third Quarter 2011 Results 6China Sky One Medical Announces Third Quarter 2011 Results 7China Sky One Medical Announces Third Quarter 2011 Results 8China Sky One Medical Announces Third Quarter 2011 Results 9China Sky One Medical Announces Third Quarter 2011 Results 10China Sky One Medical Announces Third Quarter 2011 Results 11China Sky One Medical Announces Third Quarter 2011 Results 12China Sky One Medical Announces Third Quarter 2011 Results 13China Sky One Medical Announces Third Quarter 2011 Results 14China Sky One Medical Announces Third Quarter 2011 Results 15China Sky One Medical Announces Third Quarter 2011 Results 16China Sky One Medical Announces Third Quarter 2011 Results 17China Sky One Medical Announces Third Quarter 2011 Results 18
(Date:5/27/2015)... 27, 2015 Congratulations to all 50 ... Treatment Scholarship Award. From June 1, 2014 to June ... drug and alcohol addiction treatment centers around the country ... drawn at random at addiction treatment conferences throughout the ... Matt Green said, “Sky Toxicology would like to thank ...
(Date:5/27/2015)... Hills, CA (PRWEB) May 27, 2015 ... and workflow solutions, announced today their Premier Sponsorship of ... at the Glendale Hilton on Thursday, May 28th and ... improving business as well as the roadmap to get ... consulting firm specializing in the sale, installation and support ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 Danish scientists ... line” biomarkers that have the potential to help in ... to read the full story that has just ... University in Aalborg, Denmark say new biomarkers found in ... outlook for patients with malignant mesothelioma . ...
(Date:5/27/2015)... Representatives from Classified Advertising Plus, LLC, ... the American Immigration Lawyers Association (AILA). The conference takes ... booth is #404. , The annual event is billed ... a regular AILA conference attendee, describes it as “kind ... clients to their booth and make fresh friends among ...
(Date:5/27/2015)... Viejo, CA (PRWEB) May 27, 2015 With ... Pixel Film Studios, editors can quickly and easily add filmic ... cross processed CUBE LUT files. , FCPX LUT Cross Processed ... from vintage to contemporary looks and everything in between. , ... they can be used in many different softwares. With the ...
Breaking Medicine News(10 mins):Health News:Sky Toxicology Reaches Their $500,000 Goal in Drug and Alcohol Addiction Treatment Patient Scholarship Awards 2Health News:Sky Toxicology Reaches Their $500,000 Goal in Drug and Alcohol Addiction Treatment Patient Scholarship Awards 3Health News:Altec Sponsors Connections 2015, Arxis Technology, Inc.’s Client Conference, Bringing Valuable Document Management Solution to Attendees 2Health News:Altec Sponsors Connections 2015, Arxis Technology, Inc.’s Client Conference, Bringing Valuable Document Management Solution to Attendees 3Health News:New Report Highlights Current and Emerging Biomarkers for Mesothelioma, According to Surviving Mesothelioma 2Health News:PERM Specialists from MCAads.com Will Attend the 2015 Conference on Immigration Law Set for June 17-20 in the DC Metro Area 2Health News:PERM Specialists from MCAads.com Will Attend the 2015 Conference on Immigration Law Set for June 17-20 in the DC Metro Area 3Health News:Developers at Pixel Film Studios Release FCPX LUT Cross Processed Plugin for Final Cut Pro X 2
... neuropathic pain , The pain that is associated ... trauma of amputation, entrapment, and compression, is known as ... show limited or no effectiveness. Nerve injury underlying neuropathic ... cells are thought to be contributors to the pain. ...
... LLY ) today filed a Form 8-K/A ... pro forma impact of the company,s recently-,completed acquisition of ... website at www.sec.gov and the investor relations ... The content of the Form ...
... of approval provides quality assurance to consumers and ... today that it has been awarded full accreditation ... DC-based health care accrediting organization that establishes quality ... Benefit Management accreditation provides a symbol of excellence ...
... MEXICO CITY, Jan. 12 Genomma Lab Internacional,S.A.B. de ... that on,January 9, 2009, the Company signed an agreement ... as the market maker for the Company,s outstanding shares, ... program. The,contract will become valid upon approval of the ...
... ST. LOUIS, Jan. 12 Stereotaxis, Inc.,(Nasdaq: ... of a chronic total occlusion,using the RF PowerAssert(TM) ... and,Drug Administration in 2008, the RF PowerAssert guidewire ... peripheral occlusions,including CTOs. Used with the Niobe ...
... not damage cerebral blood vessels in older women , , MONDAY, ... same group of women found that while hormone therapy is ... associated with early signs of cerebrovascular disease. , This suggests ... on the brain lesions that indicate "silent strokes," is the ...
Cached Medicine News:Health News:JCI online early table of contents: Jan. 12, 2009 2Health News:JCI online early table of contents: Jan. 12, 2009 3Health News:JCI online early table of contents: Jan. 12, 2009 4Health News:JCI online early table of contents: Jan. 12, 2009 5Health News:FutureScripts(R) Earns URAC Pharmacy Benefit Manager Accreditation 2Health News:Genomma Lab, New Participant in Market-Maker Program 2Health News:Stereotaxis Annouces First CTO Crossing Procedure With RF PowerAssert(TM) Magnetic Guidewire 2Health News:Stereotaxis Annouces First CTO Crossing Procedure With RF PowerAssert(TM) Magnetic Guidewire 3Health News:HRT Shrinks the Brain 2Health News:HRT Shrinks the Brain 3
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... is an excellent choice to treat arthritic pain, ... or following cast removal. The durable canvas ... and compression to the wrist to help relieve ... splint prevents painful wrist flexion, and holds the ...
... for controlling range of motion of the ... known for its lower extremity bracing solutions, ... patients have benefitted from our custom and ... ROM Series post-operative elbow braces come in ...
... The new "Innovation Joint Technology" elbow brace ... medical specialists to help re-establish pain free ... Brace has been engineered to provide the ... dynamic rotation forces. Treatment use includes Wrist ...
Medicine Products: